Evidence map›Paper›PMID 35768844›Full record

ArticleJournal of medical case reports2022

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report.

Hasan Nassereldine, Razan Mohty, Hussein Awada, Iman Abou Dalle, Jean El-Cheikh, Ali Bazarbachi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hasan Nassereldine *Faculty of Medicine, American University of Beirut, Beirut, Lebanon.ORCID http://orcid.org/0000-0003-2298-3098
Razan Mohty *Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box 113-6044, Beirut, Lebanon.
Hussein AwadaFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Iman Abou DalleDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box 113-6044, Beirut, Lebanon.
Jean El-CheikhDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box 113-6044, Beirut, Lebanon.
Ali BazarbachiDivision of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box 113-6044, Beirut, Lebanon. bazarbac@aub.edu.lb.
American University of Beirut Medical Center · LBAmerican University of Beirut · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMantle cell lymphoma is the rarest subtype of non-Hodgkin's lymphoma. It can exhibit diverse extranodal manifestations. However, renal involvement is uncommon, and if it occurs, it usually only gets detected postmortem. There are several mechanisms by which mantle cell lymphoma can damage the kidneys. Renal failure is a potential complication, and prompt evaluation and diagnosis are critical steps to prevent long-term complications. CASE PRESENTATION: We present the case of a 75-year-old non-Hispanic White male with past medical history significant for hypertension and dyslipidemia, presenting with fever, weight loss, and night sweats. Work-up showed markedly elevated white blood cells, multiple enlarged lymph nodes, and a kidney mass. The patient was diagnosed with mantle cell lymphoma with kidney involvement confirmed with a kidney biopsy. His disease was positive for cyclin D1 overexpression despite t(11; 14) absence. The patient received six cycles of alternating vincristine, rituximab, cyclophosphamide, doxorubicin, and prednisone then dexamethasone, high-dose cytarabine, and oxaliplatin, after which he was maintained on ibrutinib and rituximab, with resolution of symptoms and disease regression.

conclusionWe present a case of a rare presentation of Mantle cell lymphoma while describing the clinical presentation and diagnostic and treatment approaches. This case report can assist physicians in the clinical work-up and treatment of patients with similar diagnosis or presentation.

Indexed as

Lymphoma, Mantle-CellLymphoma, Non-HodgkinAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansKidneyMalePrednisoneRituximabVincristineCyclophosphamideDoxorubicinPrednisoneRituximabVincristineCase reportHematological malignancyNon-Hodgkin’s lymphomaRenal failureRenal manifestation

Identifiers

PMID35768844
PMCPMC9245262
OpenAlexW4283720759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.